NCT03376841View on ClinicalTrials.gov

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

November 24, 2017

Study Completion Date

December 17, 2017

Conditions
Hepatic Impairment
Interventions
DRUG

Cenicriviroc

1 tablet; single-dose oral administration

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03376841 - Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites | Biotech Hunter | Biotech Hunter